Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M

Barinthus Biotherapeutics plc.

Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.
Revenue of $44.7M, primarily from AstraZeneca Vaxzevria milestones/royalties, up from $0.3M in 2021.
Cash of $194.4M at Dec 31, 2022, down from $214.1M; operating cash used $14.4M, capital expenditures $5.8M.
R&D expenses of $42.4M (up 108% YoY) driven by VTP-300 HBV, SNAPvax programs, and headcount growth.
Appointed Dr. Nadège Pelletier as CSO in Jan 2023; interim data readouts for VTP-300 and VTP-200 expected in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Barinthus Biotherapeutics plc. reported the full year ended December 31, 2022 results: revenue $43.7 million.

Period: the full year ended December 31, 2022
Revenue: $43.7 million
Result: reported results

Exact text from the filing

The Company’s share of milestone and royalty payments received by Oxford University Innovation (OUI) from AstraZeneca which were recognized as revenue for the year ended December 31, 2022 amounted to $43.7 million.

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-23-036273

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.